Once the transaction is complete, Gilead will have the rights to MiroBio’s entire catalog of immune inhibitory receptors and MiroBio’s platform used to develop antibodies targeting immune inhibitory receptors. Gilead will acquire MiroBio for $405 million, according to the Aug. 4 press release.
“The team at MiroBio has spearheaded foundational research for agonist antibodies following a rigorous scientific approach,” said Flavius Martin, MD, executive vice president of research at Gilead Sciences. “We believe that MiroBio’s unique platform technology has the potential to produce best-in-class agonist antibodies targeting immune inhibitory receptors.”
